Related Experiment Video

Updated: Apr 20, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K

Fosbretabulin for the treatment of anaplastic thyroid cancer

Roberta Granata1, Laura D Locati, Lisa Licitra

  • 1Head & Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Future Oncology (London, England)
|November 15, 2014
PubMed

Insights

Fosbretabulin tromethamine, a vascular disrupting agent, demonstrated efficacy in treating anaplastic thyroid cancer. This drug was well-tolerated in preclinical models and early-phase clinical trials, alone or combined with chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Vascular Biology

Background:

  • Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options.
  • Vascular disrupting agents (VDAs) target tumor vasculature, leading to central tumor necrosis.
  • Fosbretabulin tromethamine is a novel VDA investigated for its anti-cancer properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of fosbretabulin tromethamine in anaplastic thyroid cancer.
  • To assess the activity of fosbretabulin in combination with carboplatin and paclitaxel.

Main Methods:

  • Orthotopic xenograft models of anaplastic thyroid cancer were utilized.
  • Phase I/II clinical trials were conducted to assess safety and preliminary efficacy.
  • Fosbretabulin was administered alone and in combination with standard chemotherapy agents.

Main Results:

  • Fosbretabulin demonstrated significant activity against anaplastic thyroid cancer in preclinical models.
  • Clinical trials indicated positive responses when fosbretabulin was used with or without carboplatin and paclitaxel.
  • The drug was consistently well-tolerated across all study arms.

Conclusions:

  • Fosbretabulin tromethamine shows promise as a therapeutic agent for anaplastic thyroid cancer.
  • Combination therapy with fosbretabulin and chemotherapy warrants further investigation.
  • Fosbretabulin's favorable safety profile supports its continued development for ATC treatment.
Keywords:
anaplastic thyroid cancerfosbretabulintubulin-binding agent

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K